Drugmaker GlaxoSmithKline has announced a temporary halt to its production of certain Excedrin headache pills, multiple news outlets are reporting.
According to CNN and WSYR-TV, the company said in a statement Tuesday that it “discovered inconsistencies in how we weigh ingredients for Excedrin Extra Strength Caplets and Geltabs, and Excedrin Migraine Caplets and Geltabs.” The inconsistencies should not affect customer safety, the statement read.
The company added that it is “working hard to resolve the issue as quickly as possible” but could not say when it would start producing the items again, the outlets reported.
“Other Excedrin products are available along with other pain-relieving drugs, but dosages may differ,” the statement said.
WSYR reported that some drugstores had a shortage of Excedrin products as a result.